Last Updated : October 29, 2024
Details
Project Status:
Active
Project Line:
Health Technology Review
Project Sub Line:
Observational Study
Project Number:
OS0009-000
The objective of this query is to investigate whether there is an increased risk of intentional self-harm following glucagon-like peptide-1 (GLP-1) receptor agonists, compared to sodium-glucose transport protein 2 (SGLT-2) inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors. It is a pilot project in partnership with the FDA’s Sentinel Initiative to demonstrate the contribution of electronic health data in Canada to the Sentinel Common Data Model (CDM)–based observational studies for collaboration between the US and Canada in post market drug evaluation. The topic was selected among a list of recently completed queries by the Sentinel Initiative, using their CDM. This is the third project in the suite of CDM pilot projects, including OS0005 — Safety of Ozempic for Type II Diabetes and HC0083 Utilization of Antidiabetic Drugs in Pregnancy.
Last Updated : October 29, 2024